- Updated results from a Phase 2 proof-of-concept clinical trial evaluating GTx's (GTXI +1.4%) enobosarm in postmenopausal women with stress urinary incontinence (SUI) continued to show a treatment benefit. The data were presented at the American Urological Association Annual Meeting in San Francisco.
- All 18 women who completed the 12-week treatment period experienced clinically meaningful reductions (at least 50%) in SUI episodes per day (the primary endpoint). Mean stress leaks declined 81% from baseline.
- No serious adverse events were observed.
- Patients will be followed for up to seven months post-treatment. To date, none have returned to baseline, including the 17 participants who have reached seven months.
- Topline data from an ongoing Phase 2 randomized, placebo-controlled study, ASTRID, should be available in Q4.
- Enobosarm is a non-steroidal androgen receptor agonist also being investigated for the treatment of endocrine-sensitive advanced breast cancer prior to chemotherapy.
- Previously: GTx's enobosarm shows treatment effect in mid-stage study in postmenopausal women with stress urinary incontinence; shares up 14% premarket (June 12, 2017)
GTx's enobosarm continues to demonstrate treatment effect in mid-stage SUI study
Recommended For You
About ONCT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ONCT | - | - |
Oncternal Therapeutics, Inc. |